Chugai Pharmaceutical : Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched 'Lunsumio for intravenous infusion 1 mg' and 'Lunsumio for intravenous infusion 30 mg' (generic name: mosunetuzumab